Company: OSRH
Filing Date: 2025-06-27
Form Type: 424B3
Source: 0001213900-25-058551
Chunk: 1

Company: OSR Holdings, Inc.
Filing Date: 2025-06-27
Form: 424B3
Chunk 1
---
 Common Stock sold and the price
at which shares are sold. The purchase price per share that White Lion will pay for shares of Common Stock purchased from us under the
ELOC Agreement, or upon exercise of the Warrant Agreement or conversion of the Convertible Notes, will fluctuate based on the market price
of our shares at the time we may sell shares to White Lion and, further, to the extent that the Company issues shares of Common Stock
under the Issuance Agreements, substantial amounts of shares could be issued and resold, which would cause dilution and may impact the
Company’s stock price.

Our Common Stock is listed and traded on the Nasdaq
Capital Market under the symbol “OSRH.” On May 21, 2025, the last reported sale price of our common stock was $1.15
per share. We recommend that you obtain current market quotations for our Common Stock prior to making an investment decision.

We will pay the expenses incurred in registering
the shares, including legal and accounting fees. See “Plan of Distribution” beginning on page 90 of the Prospectus.

Sales of our Common Stock, if any, under this
prospectus may be made by any method permitted that is deemed to be an “at the market offering” as defined in Rule 415(a)(4)
promulgated under the Securities Act. There is no arrangement for funds to be received in any escrow, trust, or similar arrangement.

We are an “emerging growth company,”
as that term is used in the Jumpstart Our Business Startups Act of 2012, and as such, have elected to comply with certain reduced public
company reporting requirements for the registration statement of which this prospectus forms a part and future filings. See “Prospectus
Summary—Implications of Being an Emerging Growth Company” and “Risk Factors—Risks Related to this Offering and
Ownership of Our Common Stock.”

Neither the U.S. Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus supplement. Any representation to the contrary is a criminal offense.

We may amend or supplement this prospectus from time to time by filing amendments or supplements as required. We urge you to read the entire prospectus, any amendments or supplements, any free writing prospectuses, and any documents incorporated by reference carefully before you make your investment decision.

Investing in our securities involves a high degree of risk. See “Risk